Introduction {#s1}
============

Prostate cancer (PCa) is the most common male malignant diseases in Western industrialized countries. In 2018, 164,690 cases of prostate cancer were newly diagnosed, and 29,430 cases of death were recorded in the United States ([@B1]). Despite the increasing numbers of PCa patients identified after prostate-specific antigen (PSA) screening, many cases have been initially diagnosed as metastatic cancer. Unfortunately, there is no opportunity for surgical treatment for these patients. Even if patient underwent surgical treatment, patients who did not find a micrometastatic mass before surgery would relapse. It seems that surgical treatment is difficult to achieve the effect of radical resection, thus patients have been suffering economic losses and pain all the time. It is important to identify potential micrometastases prior to surgery in order to be able to avoid surgery in PCa patients. Currently, the mechanisms of tumorigenesis and metastasis are still unclear, and biomarkers for the diagnosis of prostate cancer are urgently needed.

Previous studies have reported several diagnostic and therapeutic biomarkers in prostate cancer, such as PCA3 ([@B2]) and TRPM8 as well as its isoform ([@B3]). Ubiquitin-associated and SH3 domain-containing B (UBASH3B) is involved in cancers pathogenesis and plays an important role in oncological biology by interacting with several molecules. UBASH3B negatively regulates protein kinase activity and peptidyl-tyrosine dephosphorylation and promotes tamoxifen resistance by ESR1 negative regulation in breast cancer ([@B4]). Aberrant expression of UBASH3B in triangle-negative breast cancer boosts tumor growth, invasion, and metastasis through EGFR regulation ([@B5]). In acute myeloid leukemia (AML), UBASH3B is upregulated by AML1-ETO fusion protein to promote the growth of AML cells by functionally regulating CBL ([@B6]). In addition to the above downstream pathways, several upstream pathways have been reported. miR-200a targets UBASH3B against invasion and is downregulated in triple-negative breast cancer ([@B5]). miR-148a-3p binds to UBASH3B and negatively regulates FcγRIIA mediated platelet activation ([@B7]). The mechanism of invasion and metastasis of UBASH3B in triple-negative breast is dependent on its tyrosine phosphatase activity ([@B5]). UBASH3B not only plays a critical role in the invasion and metastasis of cancer, but also affects the immune responses in cancer. UBASH3B also named Sts1 (an inhibitor of T cell receptor signaling-1), and negatively regulates T-cell receptor signaling in activated T lymphocytes via dephosphorylation of ZAP70, and regulates IFN-α-induced autophagy in B cells ([@B8]). This suggests that UBASH3B may be a potential biomarker for prostate cancer and is involved in the immune response in cancer. However, the function of UBASH3B and the correlation of UBASH3B and tumor-infiltrating immune cells remain unclear.

In this study, we investigated mRNA and protein expression of UBASH3B in prostate cancer. All patients were followed up to generate survival curves to assess the relationship between prognosis and UBASH3B expression levels. By constructing lncRNA-miRNA-mRNA and PPI networks, it was suggested that UBASH3B may interact with LCP2 and together participate in the immune response of tumor microenvironment. Our results suggested that UBASH3B may be a novel prognostic marker and was associated with tumor-infiltrating immune cells in prostate cancer.

Materials and Methods {#s2}
=====================

Specimen Preparation
--------------------

Thirty two samples from prostate cancer patients and 9 samples from benign prostatic hyperplasia (BPH) patients were surgically harvested from the Department of Urology, Second Xiangya Hospital of Central South University with the permission of the patients. All patients signed an informed consent form, which was approved by the Clinical Research Ethics Committee of the Second Xiangya Hospital of Central South University.

Immunohistochemistry (IHC)
--------------------------

The patients\' sample were fixed in 10% neutral buffered formalin for 24 h and then embedded in paraffin. Tissue slides were prepared and deparaffinized by baking in oven 60°C for 1 h. Then antigen unmasking was done in boiling container with sodium citrate buffer for 20 min. Goat serum was used for blocking. Slides were then stained with UBASH3B antibody (1:500, Sigma, HPA038605) overnight at 4°C and secondary antibodies were incubated for 1 h at room temperature. After adding substrate and hematoxylin staining, slides were covered and observed by microscope. The expression density of UBASH3B in IHC tissue was evaluated and divided into two group: low expression group, including negative (--) and weak (+) staining, high expression group, including moderate (++) and strong (+++) staining ([@B9]).

Quantitative Real-Time PCR
--------------------------

Fresh frozen samples were used for real-time PCR. Total RNA was extracted with Trizol reagent according to the manufacturer\'s protocol (Thermo Fisher Scientific). Reverse transcription reaction was performed using random hexamers and SuperScript-III (Thermo Fisher Scientific). qPCR was cycled with the ABI 7900 real-time PCR system using SYBR Green PCRMix. The amplification efficiency was evaluated by the standard curve. Primers for UBASH3B are followed from 5′ to 3′: ttatgtgcgaggacagcaag(F), ctctgcagcaaagtcagcag(R). Primers of β-actin are followed from 5′ to 3′: cattaaggagaagctgtgct(F), gttgaaggtagtttcgtgga(R). This experiment was repeated three times.

Follow-Up
---------

Patients with prostate cancer receive a follow-up every 3 months for the first 2 years, and follow-up every 6 months for the next 2 years, followed by annual follow-up. Death events and death times were recorded. Overall survival was determined based on the time from surgical operation to death or the last follow up. For patients who were absent at the last follow-up, we conducted a telephone follow-up.

lncRNA-miRNA-mRNA Network Construction
--------------------------------------

Prostate cancer datasets including RNA-Seq and miRNA from the cancer genome atlas (TCGA-PRAD) were downloaded. The data from TCGA-PRAD was constructed into a matrix. Ensemble names of genes were transited into symbol names using Microsoft of R version 3.5.1. Patients were divided into two groups: low UBASH3B expression and high UBASH3B expression. Differentially expressed genes were identified by Package GDCRNATools and differentially expressed lncRNAs were selected by "edgeR" method (fold change more than 1.8 and *p* \< 0.01). The miRcode and mirTarBase databases were utilized to pair lncRNA-miRNA and mRNA-miRNA, respectively. Nodes and edges files were exported and visualization was performed by Cytoscape 3.6.1. Volcano map and heatmap of both mRNAs and lncRNAs were plotted and Gene Ontology (GO) and KEGG pathway were investigated.

Gene Set Enrichment Analysis (GSEA)
-----------------------------------

In the TCGA-PARD database, 499 prostate cancer cases were divided into two expression level groups according to the median expression value of UBASH3B. GSEA was then performed to detect the gene sets that were enriched in the gene rank in the two groups for identifying potential hallmark of prostate cancer. The annotated gene sets of h.all.v6.2.symbols.gmt in the Molecular Signatures Database (MSigDB) was selected in GSEA version 3.0. We performed 1,000 times of permutations. Collapse dataset to gene symbols was "False." The permutation type was "phenotype." GSEA were run and the cut-off criteria were as follows: normalized enrichment scores (NES) \> 1.0, false discovery rate (FDR) *q* \> 0.25 and nominal *p* \< 0.05. We chose all hallmark gene sets with significant enrichment and displayed gene sets enrichment plots. Then 100 most significant correlation hub genes in these gene sets was imported to construct PPI network.

Protein-Protein Interaction Network (PPI)
-----------------------------------------

The online tool of searching tool for the retrieval of interacting genes (STRING, <https://string-db.org>) was used for PPI network construction and hub genes screening. Multiple protein model was selected and 100 most significant correlation hub genes were input to search. PPI network was constructed by setting medium confidence at 0.400. Then the irrelevant genes were excluded and 19 genes were used for constructing the PPI network, then heatmap of these 19 genes was plotted. The correlations between UBASH3B and LCP2, or PIK3CG, or BIRC3 were evaluated and displayed.

Comprehensive Correlation Analysis in Tumor-Infiltrating Immune Cells
---------------------------------------------------------------------

A website called tumor immune estimation resource \[TIMER ([@B10]), <https://cistrome.shinyapps.io/timer>\] served for analysis of tumor-infiltrating immune cells, and the correlations between the infiltrating level of different subsets of immune cells and UBASH3B or LCP2 or PIK3CG or BIRC3 were computably detected. The immune cells contained CD4^+^ T cells, CD8^+^ T cells, B cells, macrophages, neutrophils, and dendritic cells. For further investigation, TPM data of RNA-seq was converted from FPKM data and used for estimating the abundance of different immune cell types in tumor microenvironment by CIBERSORT ([@B11]) (<https://cibersort.stanford.edu/>). RNA-seq data of 499 prostate cancer samples were divided into two groups: Low UBASH3B expression and High UBASH3B expression, according to the expression level of UBASH3B. Data were imported into CIBERSORT and LM22, including 22 immune cell types, selected as signature gene file. The Mixture file was made with gene symbol and sequencing values. One thousand was set as permutation value for statistical analysis. Disable quantile normalization was selected. Relative fractions of each immune cell types in each sample were calculated and Graphpad Prism 7 was used for analysis and plotting.

Statistical Analysis
--------------------

The measurement data are displayed as the mean ± SD. Unpaired *t*-test was used for analyzing statistical assessments. The association between UBASH3B and clinical characteristic variables was analyzed using Pearson chi-squared test or Fisher\'s exact test. Graphpad prism 7 was utilized for Kaplan-Meier survival analyses using the log-rank test. The Cox proportional hazards regression model was used for univariate and multivariate analyses, and statistically significant difference was considered when *P* \< 0.05.

Results {#s3}
=======

UBASH3B Is Upregulated in Prostate Cancer
-----------------------------------------

To investigate the mRNA expression level of UBASH3B in PCa and BPH tissues, real-time PCR was used and UBASH3B was found to be significantly upregulated in PCa tissues in comparison with BPH tissues (*P* = 0.0077) ([Figure 1A](#F1){ref-type="fig"}). We performed immunohistochemistry staining for UBASH3B expression in prostate cancer and BPH tissues. Quantitative analysis of IHC found that the expression of UBASH3B was significantly upregulated in the prostate cancer tissues compared with BPH. UBASH3B expression was further found to be higher in PCa patients with metastasis than localized PCa patients ([Figure 1B](#F1){ref-type="fig"}). Differential expression levels of UBASH3B in BPH and PCa tissue were displayed in ([Figure 1C](#F1){ref-type="fig"}). To further investigate the correlation between UBASH3B expression level and disease progression, we explored the relationship between expression level of UBASH3B and clinical characteristics in 32 patients ([Table 1](#T1){ref-type="table"}). No correlation was revealed between UBASH3B expression level and age, TNM stage, metastasis, Gleason score, or total PSA. Kaplan-Meier analysis suggested that prostate cancer patients with high UBASH3B expression level experienced a significantly shorter overall survival of 5-year than those with low UBASH3B levels (*p* = 0.042) ([Figure 1D](#F1){ref-type="fig"}). Univariate and multivariate COX regression analysis indicated UBASH3B was associated with poor survival but was not an independent prognostic factor ([Table 2](#T2){ref-type="table"}).

![**(A)** The mRNA expression of UBASH3B is significantly upregulated in prostate cancer tissue as compared with normal prostate tissue (*p* = 0.0077). **(B)** The expression of UBASH3B is significantly associated with tumor metastatic status of prostate cancer (*p* = 0.0016). **(C)** Differential expression level of UBASH3B in benign prostate hyperplasia (BPH) tissue and prostate cancer (PCa) tissue. Weak expression (+); Moderate expression (++); Strong expression (+ + +). **(D)** Data indicate that the expression levels of UBASH3B are associated with poor prognostic survival in prostate cancer patients (*p* = 0.0412).](fonc-09-01517-g0001){#F1}

###### 

Relationship between UBASH3B expression level and clinicopathological variables and in prostate cancer patients.

  **Classification**   **Total**   **Low UBASH3B expression**   **High UBASH3B expression**   ***p***
  -------------------- ----------- ---------------------------- ----------------------------- ---------
  **AGE(YEAR)**                                                                               
  \< 60                4           1                            3                             1.000
  ≥ 60                 28          8                            20                            
  **TNM STAGE**                                                                               
  T1--T2               20          6                            14                            1.000
  T3--T4               12          3                            9                             
  **METASTASIS**                                                                              
  --                   23          7                            16                            1.000
  \+                   9           2                            7                             
  **GLEASON SCORE**                                                                           
  ≤ 6                  7           4                            3                             0.191
  7                    13          2                            11                            
  ≥ 8                  12          3                            9                             
  **TOTAL PSA**                                                                               
  ≤ 20 ng/ml           5           1                            4                             1.000
  \>20 ng/ml           27          8                            19                            

*Low expression including no (--) and weak (+) staining*.

*High expression including moderate (++) and strong (+++) staining*.

*Metastasis including lymph node and distant metastasis*.

###### 

Univariate and multivariate regression analysis to determine the independent prognostic factor.

  **Variables**       **Univariate**   **Multivariate**                                      
  ------------------- ---------------- ------------------ ------ ------- ------------------- ------
  Age                 0.083            1.1 (1--1.2)       0.02   0.07    1.07 (0.99--1.17)   0.08
  tPSA                −0.41            0.67 (0.18--2.4)   0.53   −0.55   0.58 (0.13--2.48)   0.46
  TNM                 0.57             1.8 (0.63--4.9)    0.28   0.58    1.78 (0.17--17.9)   0.62
  UBASH3B             1.8              6.3 (0.83--48)     0.04   1.3     3.65 (0.44--30.7)   0.23
  Gleason score       0.19             1.2 (0.62--2.4)    0.58   0.19    1.21 (0.58--2.52)   0.61
  Metastasis status   0.72             2.1 (0.73--5.8)    0.17   0.79    0.79 (0.06--9.95)   0.86

lncRNA-miRNA-mRNA Network Construction
--------------------------------------

Analysis for differentially expressed lnRNA and mRNA were performed using "edgeR." Three hundred four differentially expressed mRNAs and 55 differentially expressed lncRNAs were calculated to find shared miRNAs for "nodes" and "edges" files. We obtained 134 nodes and 227 edges and utilized to construct lncRNA-miRNA-mRNA network ([Figure 2A](#F2){ref-type="fig"}). The subnetwork of UBASH3B contained 3 lncRNAs (MIAT, LINC01297, MYLK-AS1) and 4 miRNAs (hsa-miR-200a-3p, hsa-miR-455-5p, hsa-miR-192-5p, hsa-miR-215-5p). Volcano map of both mRNA and lncRNA showed up-regulated and down-regulated genes ([Figure 2B](#F2){ref-type="fig"}). Then heatmap was shown in [Figure 2C](#F2){ref-type="fig"}.

![**(A)** lncRNA-miRNA-mRNA network was constructed from R package of GDCRNATools according to different UBASH3B expression levels and visualized by microsoft Cytoscape. Blue, mRNA; Green, miRNA; Red, lncRNA. **(B)** Volcano plot of differentially expressed mRNAs and lncRNAs is based on differences in expression levels of UBASH3B. **(C)** Heatmap of mRNAs and lncRNAs in TCGA-PRAD according to different UBASH3B expression level (Blue, samples with low UBASH3B expression; Red, samples with high UBASH3B expression).](fonc-09-01517-g0002){#F2}

GO and KEGG Pathway
-------------------

Gene ontology contains biological process, cellular components, and molecular function. The top 10 of each aspect were shown in [Figure 3A](#F3){ref-type="fig"}. The enriched biological process involved in GO: 0006936:muscle contraction, GO:2000027:regulation of organ morphogenesis, GO:0051146:striated muscle cell differentiation, GO: 0042692:muscle cell differentiation, GO: 0002009: morphogenesis of an epithelium, GO: 0051272: positive regulation of cellular component movement, GO: 0030198: extracellular matrix organization, GO: 0030900:forebrain development, GO: 0098742: cell-cell adhesion via plasma-membrane adhesion molecules, GO: 0043583: ear development. The enriched cellular components involved in GO: 0031012: extracellular matrix, GO: 0043292: contractile fiber, GO: 0042383: sarcolemma, GO: 0045121: membrane raft, GO: 0009897: 0030055: cell-substrate junction, GO: 0034702: ion channel complex, GO: 0015629: actin cytoskeleton, GO: 0016323: basolateral plasma membrane, GO: 0044297: cell body. The enriched molecular function involved in GO:0005539: glycosaminoglycan binding, GO: 0015267: channel activity, GO: 0022803: passive transmembrane transporter activity, GO: 0005518: collagen binding, GO: 0033293: monocarboxylic acid binding, GO: 0004714: transmembrane receptor protein tyrosine kinase activity, GO: 0008083: growth factor activity, GO: 0008307: structural constituent of muscle, GO: 0004601: peroxidase activity, GO: 0005200: structural constituent of cytoskeleton. There were 28 KEGG pathways involved in variations of UBASH3B expression ([Table 3](#T3){ref-type="table"}) and top 10 pathways were displayed in [Figure 3B](#F3){ref-type="fig"}. The top 10 pathways are cytokine-cytokine receptor interaction, cell adhesion molecules (CAMs), chemokine signaling pathway, NOD-like receptor signaling pathway, transcriptional misregulation in cancer, IL-17 signaling pathway, Rheumatoid arthritis, Malaria, Mineral absorption, Legionellosis.

![**(A)** Gene Ontology (GO) have been analyzed and shows the Top 10 of BP, CC, and MF(BP, Biological Process; CC, Cellular Component; MF, Molecular Function). **(B)** KEGG pathways is analyzed and the Top 10 pathway is mapped according to the differential expression level of UBASH3B.](fonc-09-01517-g0003){#F3}

###### 

KEGG pathway involved in PRAD according to UBASH3B expression level.

  **ID**     **Description**                                        **GeneRatio**   **BgRatio**   **p.adjust**
  ---------- ------------------------------------------------------ --------------- ------------- --------------
  hsa04514   Cell adhesion molecules (CAMs)                         15/150          144/7840      1.77E-05
  hsa04062   Chemokine signaling pathway                            15/150          190/7840      0.000238547
  hsa05144   Malaria                                                8/150           49/7840       0.000238547
  hsa04657   IL-17 signaling pathway                                10/150          93/7840       0.000477884
  hsa04060   Cytokine-cytokine receptor interaction                 18/150          294/7840      0.000477884
  hsa04621   NOD-like receptor signaling pathway                    13/150          178/7840      0.001155184
  hsa04978   Mineral absorption                                     7/150           51/7840       0.001280394
  hsa05202   Transcriptional misregulation in cancer                13/150          186/7840      0.001280394
  hsa05323   Rheumatoid arthritis                                   9/150           91/7840       0.001280394
  hsa05134   Legionellosis                                          7/150           55/7840       0.001587716
  hsa04640   Hematopoietic cell lineage                             9/150           97/7840       0.001732903
  hsa04512   ECM-receptor interaction                               8/150           82/7840       0.002766479
  hsa05410   Hypertrophic cardiomyopathy (HCM)                      8/150           85/7840       0.003285433
  hsa04668   TNF signaling pathway                                  9/150           110/7840      0.003582737
  hsa05414   Dilated cardiomyopathy (DCM)                           8/150           91/7840       0.004565533
  hsa05133   Pertussis                                              7/150           76/7840       0.007632455
  hsa04933   AGE-RAGE signaling pathway in diabetic complications   8/150           100/7840      0.007632455
  hsa05167   Kaposi sarcoma-associated herpesvirus infection        11/150          186/7840      0.009718886
  hsa04151   PI3K-Akt signaling pathway                             16/150          354/7840      0.0126229
  hsa04510   Focal adhesion                                         11/150          199/7840      0.015177136
  hsa05150   *Staphylococcus aureus* infection                      6/150           68/7840       0.01803509
  hsa04672   Intestinal immune network for IgA production           5/150           49/7840       0.021119439
  hsa05146   Amoebiasis                                             7/150           96/7840       0.021119439
  hsa05142   Chagas disease (American trypanosomiasis)              7/150           103/7840      0.03011686
  hsa05143   African trypanosomiasis                                4/150           37/7840       0.043099315
  hsa04670   Leukocyte transendothelial migration                   7/150           112/7840      0.044096453
  hsa05145   Toxoplasmosis                                          7/150           113/7840      0.044559068

Enriched Gene Sets in Low- and High- UBASH3B Expression Group
-------------------------------------------------------------

In high UBASH3B expression phenotype, 34 out of 50 gene sets were upregulated and 18 gene sets were significantly enriched at nominal *p* \< 0.05, NES \> 1.0 and FDR *q* \> 0.25. The significantly upregulated hallmark gene sets involving in immune response were as follows: "KRAS SIGNALING UP," "INFLAMMATORY RESPONSE," "IL6 JAK STAT3 SIGNALING," "IL2 STAT5 SIGNALING," "COMPLEMENT," "INTERFERON GAMMA RESPONSE," "TGF BETA SIGNALING," "TNFA SIGNALING VIA NFKB," whereas gene sets involving in tumorigenesis and metastasis were "EPITHELIAL MESENCHYMAL TRANSITION," "APOPTOSIS," "MITOTIC SPINDLE," "ANGIOGENESIS" in high UBASH3B expression group. All gene sets were shown in [Table 4](#T4){ref-type="table"} and snapshot of enrichment results were shown in [Figure 4](#F4){ref-type="fig"}.

###### 

GSEA pathways up-regulated and down-regulated due to expression level of UBASH3B.

  **GENE SETS**                                                  **SIZE**   **NES**   **NOM p-val**   **FDR q-val**
  -------------------------------------------------------------- ---------- --------- --------------- ---------------
  **Upregulated gene sets in high UBASH3B expression group**                                          
  HALLMARK_KRAS_SIGNALING_UP                                     193        −2.168    0.000           0.003
  HALLMARK_INFLAMMATORY_RESPONSE                                 195        −2.147    0.002           0.002
  HALLMARK_IL6_JAK_STAT3_SIGNALING                               86         −2.070    0.002           0.004
  HALLMARK_ALLOGRAFT_REJECTION                                   197        −2.027    0.004           0.006
  HALLMARK_IL2_STAT5_SIGNALING                                   194        −2.019    0.002           0.005
  HALLMARK_COMPLEMENT                                            194        −1.995    0.002           0.007
  HALLMARK_TGF_BETA_SIGNALING                                    54         −1.967    0.004           0.010
  HALLMARK_UV_RESPONSE_DN                                        140        −1.926    0.002           0.013
  HALLMARK_INTERFERON_GAMMA_RESPONSE                             197        −1.894    0.018           0.016
  HALLMARK_HEDGEHOG_SIGNALING                                    35         −1.858    0.002           0.020
  HALLMARK_APICAL_JUNCTION                                       191        −1.828    0.013           0.025
  HALLMARK_TNFA_SIGNALING_VIA_NFKB                               198        −1.818    0.025           0.026
  HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION                     197        −1.787    0.032           0.030
  HALLMARK_APOPTOSIS                                             158        −1.749    0.019           0.036
  HALLMARK_MITOTIC_SPINDLE                                       197        −1.735    0.022           0.038
  HALLMARK_ANGIOGENESIS                                          36         −1.659    0.031           0.062
  HALLMARK_COAGULATION                                           132        −1.608    0.051           0.079
  HALLMARK_APICAL_SURFACE                                        42         −1.603    0.031           0.077
  **Downregulated gene sets in high UBASH3B expression group**                                        
  HALLMARK_OXIDATIVE_PHOSPHORYLATION                             183        1.803     0.032           0.180

![GSEA pathways using single-gene method of UBASH3B. **(A--K)** Up-regulated gene sets in the group of high UBASH3B expression. **(A)** Enrichment plot: HALLMARK_KRAS_SIGNALING_UP. **(B)** Enrichment plot: HALLMARK_ALLOGRAFT_REJECTION. **(C)** HALLMARK_IL2_STAT5_SIGNALING. **(D)** Enrichment plot: HALLMARK_INFLAMMATORY_RESPONSE. **(E)** Enrichment plot: HALLMARK_IL6_JAK_STAT3_SIGNALING. **(F)** Enrichment plot: HALLMARK_INTERFERON_GAMMA_RESPONSE. **(G)** Enrichment plot: HALLMARK_COMPLEMENT. **(H)** Enrichment plot: HALLMARK_UV_RESPONSE_DN. **(I)** Enrichment plot: HALLMARK_TGF_BETA_SIGNALING. **(J)** Enrichment plot: HALLMARK_HEDGEHOG_SIGNALING. **(K)** Enrichment plot: HALLMARK_TNFA_SIGNALING_VIA_NFKB. **(L)** Down-regulated gene sets in the group of high UBASH3B expression: Enrichment plot: HALLMARK_OXIDATIVE_PHOSPHORYLATION.](fonc-09-01517-g0004){#F4}

UBASH3B Is Correlated With LCP2, PIK3CG, and BIRC3 in Prostate Cancer
---------------------------------------------------------------------

To construct PPI network, 100 UBASH3B correlated genes were analyzed and 19 genes participated in the network after elimination of disconnected node. It is suggested that LCP2 was an interactive protein of UBASH3B ([Figure 5A](#F5){ref-type="fig"}). Heatmap of these 19 genes was displayed in [Figure 5B](#F5){ref-type="fig"}. Furthermore, both PIK3CG and BIRC3 have been found in lncRNA-miRNA-mRNA network and PPI network. TIMER was used for correlation analysis and it indicated that UBASH3B was significantly correlated with LCP2 (*p* = 3.37e-40, cor = 0.547), PIK3CG (*p* = 2.44e-38, cor = 0.536), and BIRC3 (*p* = 0, cor = 0.534) in prostate cancer ([Figure 5C](#F5){ref-type="fig"}).

![**(A)** The top 50 genes of each phenotype in the GSEA single-gene method was used to construct the PPI network by STRING (<https://string-db.org/>) and 19 genes was mapped (medium confidence equals 0.400). **(B)** Heatmap of 19 genes is involved in PPI network. **(C)** UBASH3B is significantly correlated with LCP2 (*p* = 3.37e-40, cor = 0.547), PIK3CG (*p* = 2.44e-38, cor = 0.536), and BIRC3 (*p* = 0, cor = 0.534) in prostate adenocarcinoma.](fonc-09-01517-g0005){#F5}

A Significant Correlation Between UBASH3B and Tumor-Infiltrating Immune Cells in Tumor Microenvironment
-------------------------------------------------------------------------------------------------------

In order to know the relationship between UBASH3B expression and tumor-infiltrated immune cells, the tool of TIMER was used to analysis. There was a significant correlation between UBASH3B expression and different type of immune cells, including CD4^+^ T cells (*p* = 2.37e-13, cor = 0.351), CD8^+^ T cells (*p* = 1.58e-11, cor = 0.323), B cells (*p* = 9.33e-18, cor = 0.406), macrophages (*p* = 6.89e-14, cor = 0.356), Neutrophils (*p* = 1.65e-26, cor = 0.491), and dendritic cells (*p* = 2.30e-23, cor = 0.462) ([Figure 6A](#F6){ref-type="fig"}). We also found that the UBASH3B-related genes, LCP2, PIK3CG and BIRC3 were correlated with a group of immune cells. For LCP2, CD4^+^ T cells (*p* = 2.73e-43, cor = 0.61), CD8^+^ T cells (*p* = 1.86e-24, cor = 0.472), B cells (*p* = 4.21e-39, cor = 0.584), macrophages (*p* = 7.24e-25, cor = 0.476), Neutrophils (*p* = 6.81e-55, cor = 0.668), and dendritic cells (*p* = 6.84e-81, cor = 0.765) were identified ([Figure 6B](#F6){ref-type="fig"}). Further, the relationship between expression of PIK3CG and immune cells was described, including CD4^+^ T cells (*p* = 4.60e-31, cor = 0.351), CD8^+^ T cells (*p* = 2.18e-49, cor = 0.64), B cells (*p* = 1.84e-53, cor = 0.663), macrophages (*p* = 9.63e-42, cor = 0.598), Neutrophils (*p* = 2.70e-54, cor = 0.666) and dendritic cells (*p* = 3.02e-85, cor = 0.778) ([Figure 6C](#F6){ref-type="fig"}). There was a significant correlation between BIRC3 expression and immune cells, including CD4^+^ T cells (*p* = 6.12e-34, cor = 0.551), CD8^+^ T cells (*p* = 9.67e-08, cor = 0.258), B cells (*p* = 1.23e-20, cor = 0.437), macrophages (*p* = 8.45e-08, cor = 0.259), Neutrophils (*p* = 6.92e-55, cor = 0.668), and dendritic cells (*p* = 2.31e-32, cor = 0.537) ([Figure 6D](#F6){ref-type="fig"}). Altogether, it was suggested that UBASH3B may participate in immune response in tumor microenvironment through affecting immune cells.

![**(A)** There is a significant correlation between UBASH3B expression and immune cells, including CD4^+^ T cells, CD8^+^ T cells, B cells, macrophages, Neutrophils, and dendritic cells. **(B)** There is a significant correlation between LCP2 expression and immune cells, including CD4^+^ T cells, CD8^+^ T cells, B cells, macrophages, Neutrophils, and dendritic cells. **(C)** There is a significant correlation between PIK3CG expression and immune cells, including CD4^+^ T cells, CD8^+^ T cells, B cells, macrophages, Neutrophils, and dendritic cells. **(D)** There is a significant correlation between BIRC3 expression and immune cells, including CD4^+^ T cells, CD8^+^ T cells, B cells, macrophages, Neutrophils, and dendritic cells.](fonc-09-01517-g0006){#F6}

For further investigation, CIBERSORT analysis indicated that the UBASH3B expression was correlated with tumor-filtrating immune cells, including naïve B cell (*p* \< 0.0001), memory B cells (*p* = 0.0424), resting CD4^+^ memory T cell (*p* = 0.0008), activated CD4^+^ memory T cell (*p* = 0.0274), regulatory T cell (*p* = 0.0368), activated NK cell (*p* = 0.0015), M2 macrophages (*p* = 0.0001), resting dendritic cells (*p* \< 0.0001), activated dendritic cells (*p* = 0.0097), resting mast cells (*p* = 0.0009), neutrophils (*p* = 0.0499) ([Figure 7](#F7){ref-type="fig"}). These altogether suggested that UBASH3B and its associated genes were important for immune cells infiltration in tumor pathology.

![Based on TCGA-PRAD database, LM22 signature matrix is used for analysis using CIBERSORT online. Twenty-two kinds of tumor infiltrating immune cells are plotted according to UBASH3B expression level. There are significant differences in naïve B cell, memory B cells, resting CD4^+^ memory T cell, activated CD4^+^ memory T cell, regulatory T cell, activated NK cell, M2 macrophages, resting dendritic cells, activated dendritic cells, resting mast cells, neutrophils (\*\*\*\<0.001\< \*\*\<0.01\< \*\<0.05).](fonc-09-01517-g0007){#F7}

Discussion {#s4}
==========

Prostate cancer is among the most common male genitourinary tumors worldwide. With the development of PSA screening and several treatment methods, patients with prostate cancer benefit from early diagnosis and intervention. However, in China, locally advanced prostate cancer accounts for only one-third of newly diagnosed prostate cancer patients, and the rest are diagnosed with invasive prostate cancer with advanced or metastatic symptoms and without surgical opportunities. Androgen deprivation therapy is the first-line treatment for hormone-sensitive prostate cancers with distal metastases. However, this carcinoma will eventually develop into castration-resistant prostate cancer (CRPC), and the therapeutic drugs will not obtain long-term remission, resulting in a poor prognosis. Therefore, it is necessary to further understand the drug-resistance related genes as a novel prognostic marker in prostate cancer. In this study, we identified UBASH3B as a novel potential prognostic biomarker for prostate cancer and investigated the correlation between UBASH3B and tumor-infiltrating immune cells in PCa.

UBASH3B, also known as STS1, TULA-2, or p70, is a member of the tyrosine phosphatase family of proteins that contain a ubiquitin-associated domain at the N-terminus, an SH3 domain, and a C-terminal domain with similarities to the catalytic motif of phosphoglycerate mutase. Functional studies linked UBASH3B expression to evaluate diseases states such as in thrombosis, leukemia, and triple-negative breast cancer. van der Meulen et al. have found that EGF receptor activation affects the interaction between UBASH3B and ShcA ([@B12]). UBASH3B plays a vital role through targeting Aurora B to microtubules in the timing and fidelity of chromosome segregation in human cells. UBASH3B also regulates myeloid proliferation through UBASH3B-CBL axis in human pre-leukemia ([@B6]). miR-148a-3p targets UBASH3B, which serves as a negative regulator of FcγRIIA-mediated platelet activation ([@B7]). UBASH3B is a functional target for drug-resistance and downregulated anti-invasive microRNA200a in triple-negative breast cancer ([@B5]). Importantly, the oncogenic potential of UBASH3B is dependent on its tyrosine phosphatase activity to promote invasion and metastasis. UBASH3B has been detected in prostate cancer cell lines and UBASH3B knockdown can decrease EGF-induced invasion and form tumor spheres in PC3 and DU145 cells ([@B5]). Real time PCR and western blot analysis results of our study showed mRNA and protein expression of UBASH3B were increased in prostate cancer samples as compared with that in benign prostatic hyperplasia samples. Kaplan-Meier survival analysis indicated that UBASH3B is a prognostic factor for 5-year survival in patients with prostate cancer. However, there was no significant relationship between UBASH3B expression and age/clinical stage/Gleason score/metastasis/total PSA. The high-risk status of the patients may affect the outcome of this study. The high-risk criteria of prostate cancer patients include a total PSA of more than 20 ng/ml, the clinical stage later than T1c, or the Gleason score of more than 7. More cases and prospective studies are required in the future. Varambally et al. revealed that UBASH3B mRNA expression was significantly differed between primary prostate cancer sites and metastatic sites ([@B13]), the same expression pattern has been observed in prostate cell lines. It was suggested that UBASH3B could drive prostate cancer metastasis, so the mechanism of tumor metastasis that is associated with UBASH3B may be our next investigation. Previous studies have shown that UBASH3B is involved in the regulation of T cell receptor signaling in activated T lymphocytes and regulates IFN-α-induced B cell autophagy ([@B8]). These altogether suggested UBASH3B might participate in immune response. The lncRNA-miRNA-mRNA network is involved in a number of prognostic-related genes, which also play a vital role in immune response, such as PIK3CG ([@B14], [@B15]) and BIRC3 ([@B16], [@B17]). In our study, we performed GSEA to explore the hallmarks of gene sets in high UBASH3B expression group and identified 18 up-regulated gene sets and 1 down-regulated gene sets such as "KRAS signaling up," "inflammatory response," "IL6 JAK STAT3 signaling," and "oxidative phosphorylation." The results of PPI network and TIMER indicate that UBASH3B may directly bind to LCP2, which is a gene involved in the inflammatory response. In addition, PIK3CG and BIRC3 were also found in PPI network and correlated with immune cells infiltrating in tumor microenvironment.

In recent years, the microenvironment involving many cell clusters (such as immune cells, tumor cells, and fibroblasts) in cancer is a hot issue. How UBASH3B participate in tumor microenvironment and influence tumor-infiltrating immune cells in prostate cancer should be explored. Based on the expression level of UBASH3B, we found six types of tumor-infiltrating immune cells in prostate cancer tissues, including B cells, CD4^+^ T cells, CD8^+^ T cells, macrophages, neutrophil, and dendritic cells. The infiltration of immune cells were found to be positively correlated with UBASH3B. Moreover, LCP2, PIK3CG, and BIRC3 were also positively correlated with these six types of immune cells in prostate cancer. CIBERSORT analysis assessed the estimated fraction of tumor-infiltrating immune cells in prostate cancer based on differentially expressed UBASH3B. There were 11 types of immune cells, including in naïve B cell, memory B cells, resting CD4^+^ memory T cell, activated CD4^+^ memory T cell, regulatory T cell, activated NK cell, M2 macrophages, resting dendritic cells, activated dendritic cells, resting mast cells and neutrophils, infiltrate in prostate cancer. These data suggest that UBASH3B expression levels are closely related to PCa-infiltrated immune cells, and further studies will be interesting to explore specific mechanisms of UBASH3B regulating these tumor-infiltrating immune cells in PCa. The crosstalk between UBASH3B and tumor-infiltrating immune cells in PCa suggests a potential target of UBASH3B for future treatment of PCa.

Since this study is based on preliminary data and hypothesis-generating predictions, there are some limitations in this study. First, the sample size in the cohort study of prostate cancer for IHC is limited and more precise data could be obtained with a larger number of samples. Second, the regulatory subnetwork of UBASH3B needs to be validated. In addition, the mechanisms of UBASH3B to regulate the infiltration of immune cells is required for further study.

In conclusion, our study has indicated that UBASH3B may represent a potential biomarker that contributes to poor prognosis for prostate cancer. UBASH3B may also play a vital role in the microenvironment of prostate cancer through regulating tumor-infiltrating of immune cells, suggesting UBASH3B as a therapeutic target to modulate anti-tumor immune response.
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